In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. Another endpoint measured was reduction in itch from baseline to Week 16 (all trials) and 52 (Trial 3) as defined by ≥4‑point improvement in the peak pruritus numerical rating key scale (NRS). The NRS is a patient-reported measure that assesses maximum itch intensity in the previous 24 hours using a point scale of 0 to 10. These daily reports were averaged for each study week to produce a weekly NRS score.1-4
For all patients, moderate-to-severe atopic dermatitis was treated with concomitant TCS. Results are presented at 16 and 52 weeks.1
NRS, numerical rating scale; TCS, topical corticosteroids.